JANX

NASDAQ 已收盘

Janux Therapeutics

10.29 USD
▼-0.02-0.19%
盘后 10.28 -0.10%
2026-11-19
市值
$616.73M
市盈率
—
EPS
-1.59
股息率
—
52 周区间
10.16 – 35.34
成交量
651.23K
Beta
2.39
目标价
33.14
52W 低 10.1652W 高 35.34
价格走势

公司简介

Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms technology to treat patients with cancer. The company’s clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer and the vasculature of other tumors; and JANX008...